Holen Sie sich die Stockscreener-App
0.861
80.25%
-3.499
Vorhandelsmarkt:
.85
-0.011
-1.28%
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Downgrade Alert: Vistagen Therapeutics (VTGN) Target Price Slashed | VTGN Stock News - GuruFocus
Vistagen stock craters after social anxiety study comes up empty - FirstWord Pharma
Vistagen Therapeutics (VTGN) Downgraded by Maxim Group | VTGN St - GuruFocus
Vistagen Therapeutics (VTGN) Receives Downgrade from William Bla - GuruFocus
Jefferies downgrades VistaGen stock rating to Hold on failed Phase III trial - Investing.com
Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst - Fierce Biotech
Vistagen’s anxiety treatment fails to meet primary endpoint in trial By Investing.com - Investing.com Nigeria
Fasedienol for Social Anxiety Disorder Does Not Demonstrate Significant Improvement in Phase 3 Study - Psychiatric Times
VistaGen stock rating downgraded by William Blair after trial miss - Investing.com UK
Maxim Downgrades Vistagen Therapeutics to Hold From Buy - marketscreener.com
William Blair Downgrades VistaGen Therapeutics(VTGN.US) to Hold Rating - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Stifel downgrades VistaGen stock to Hold as anxiety drug fails in trial - Investing.com
Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints - TipRanks
Why Did Vistagen Stock Tank 82% Today? - Stocktwits
Vistagen (VTGN) Faces Setback as Phase 3 Trial Misses Primary En - GuruFocus
Vistagen downgraded to Neutral from Buy at Lucid Capital - TipRanks
Vistagen (VTGN) Phase 3 Study Results for Social Anxiety Treatme - GuruFocus
Vistagen SAD study did not achieve primary endpoint - TipRanks
Vistagen’s anxiety treatment fails to meet primary endpoint in trial - Investing.com
Vistagen flunks late-stage trial for social anxiety drug (VTGN) - Seeking Alpha
Vistagen Announces Topline Results From Palisade-3 Phase 3 Study - TradingView — Track All Markets
Social anxiety nose-spray drug stumbles in key trial, but safety holds up - Stock Titan
Vistagen Therapeutics Earnings Notes - Trefis
Fed Meeting: Can Vistagen Therapeutics Inc stock beat analyst upgradesJuly 2025 Review & Low Drawdown Investment Strategies - moha.gov.vn
VistaGen Therapeutics (NASDAQ:VTGN) Share Price Crosses Above 50-Day Moving AverageShould You Sell? - MarketBeat
Would You Still Hold Vistagen Therapeutics Stock If It Fell 30%? - Trefis
Is Vistagen Therapeutics Inc (VTGN) positioned for future growth? - setenews.com
Can Vistagen Therapeutics Stock Recover If Markets Fall? - Trefis
Is Vistagen Therapeutics Stock Built to Withstand More Downside? - Trefis
Why Vistagen Therapeutics Inc. stock is trending among retail tradersJuly 2025 Final Week & Free Community Consensus Stock Picks - Newser
Will Vistagen Therapeutics Inc. stock pay special dividends2025 Year in Review & Reliable Entry Point Trade Alerts - Newser
VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
VistaGen Therapeutics Appoints New CFO Nick B. Tressler - TipRanks
Vistagen Appoints Nick Tressler as Chief Financial Officer - BioSpace
VistaGen appoints Nick Tressler as CFO - MSN
The time has not yet come to remove your chips from the table: Vistagen Therapeutics Inc (VTGN) - Setenews
Vistagen Therapeutics Appoints Nick Tressler as CFO - marketscreener.com
Vistagen (VTGN) Appoints New CFO, Nick Tressler - GuruFocus
Vistagen (VTGN) Names Nick Tressler as New CFO - GuruFocus
Vistagen Names Nick Tressler as Chief Financial Officer - Contract Pharma
Vistagen appoints Nick Tressler as chief financial officer - marketscreener.com
Vistagen (Nasdaq: VTGN) appoints CFO Nick Tressler, grants 150,000-share option - Stock Titan
Why retail investors pile into Vistagen Therapeutics Inc. stock2025 Sector Review & Technical Pattern Based Signals - BỘ NỘI VỤ
Vistagen Therapeutics Inc. (VTGN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vistagen (VTGN) Presents Promising Data on PH80 for Menopause Sy - GuruFocus
Vistagen presents data on PH80 for menopausal hot flashes treatment By Investing.com - Investing.com Canada
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting - Yahoo Finance
Vistagen presents data on PH80 for menopausal hot flashes treatment - Investing.com
Form 8-KCurrent report - ADVFN
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update - ADVFN
What analysts say about Vistagen Therapeutics Inc stockTop Performing Stocks & Free ETF and Mutual Fund Comparisons - earlytimes.in
Is Vistagen Therapeutics Inc a good long term investmentTechnical Breakout Signals & High Return Capital Strategies - earlytimes.in
Can Vistagen Therapeutics Inc. stock hit analyst price targetsSwing Trade & Expert Verified Stock Movement Alerts - newser.com
What technical charts say about Vistagen Therapeutics Inc. stockJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - newser.com
Will Vistagen Therapeutics Inc. stock split attract more investorsJuly 2025 Pullbacks & Expert Verified Movement Alerts - newser.com
ETFs Investing in Vistagen Therapeutics, Inc. Stocks - TradingView
Can Vistagen Therapeutics Inc. stock deliver surprise earnings beatQuarterly Market Review & Long Hold Capital Preservation Plans - newser.com
0.18%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):